Rezolute Q1 FY27 net loss widens year over year to $18.49 million
RZLT•Rezolute’s first-quarter FY27 net loss widened year over year to $18.49 million, while cash, cash equivalents and marketable securities fell 17% to $90 million at September 30, 2026. The company said enrollment in its Phase 3 upLIFT tumor HI study is complete, with topline results expected by mid-December 2026.
1. Quarterly results and pipeline
Rezolute reported a first-quarter FY27 net loss of $18.49 million, wider year over year. Cash, cash equivalents and investments in marketable securities were $90 million at September 30, 2026, down 17% from June 30. Enrollment in the Phase 3 upLIFT tumor HI study is complete, and topline results are expected by mid-December 2026; a BLA submission for ersodetug in one or potentially both indications is planned for 2027.
